公开(公告)号：KR20180054858A

公开(公告)日：2018-05-24

申请号：KR20187012175

申请日：2016-09-30

Applicant: SERVIER LAB ,  VERNALIS R&D LTD

Inventor： BALINT BALAZS ,  KOTSCHY ANDRAS ,  SIPOS MELINDA ,  WEBER CSABA ,  FOLOPPE NICOLAS ,  WALMSLEY DAVID ,  BURBRIDGE MICHAEL FRANK ,  CRUZALEGUI FRANCISCO HUMBERTO

IPC: C07D471/04 ,  A61K31/437 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P35/00

CPC classification number: C07D471/04

Abstract: 암, 신경변성장애및 대사장애의치료에유용한하기화학식 (I)의화합물:(화학식 I)

公开(公告)号：KR20180054856A

公开(公告)日：2018-05-24

申请号：KR20187012166

申请日：2016-09-30

Applicant: SERVIER LAB ,  VERNALIS R&D LTD

Inventor： FIUMANA ANDREA ,  FOLOPPE NICOLAS ,  RAY STUART ,  WALMSLEY DAVID ,  KOTSCHY ANDRAS ,  BURBRIDGE MICHAEL FRANK ,  CRUZALEGUI FRANCISCO HUMBERTO

IPC: C07D487/04 ,  A61K31/437 ,  A61K31/519 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P35/00 ,  C07D471/04

CPC classification number: C07D471/04 ,  C07D487/04

Abstract: 암, 신경변성장애및 대사장애의치료에유용한하기화학식 (I)의화합물:(화학식 I)

公开(公告)号：KR20180041233A

公开(公告)日：2018-04-23

申请号：KR20187008533

申请日：2016-08-26

Applicant: SERVIER LAB

Inventor： FONKNECHTEN GILLES

IPC: A61K31/40 ,  A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K31/404 ,  A61K31/616 ,  A61P9/00 ,  A61P9/12

CPC classification number: A61K31/40 ,  A61K9/1611 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2813 ,  A61K9/2846 ,  A61K31/404 ,  A61K31/616 ,  A61K2300/00

Abstract: HMG-CoA 환원효소억제제인아토르바스타틴및 항고혈압제인페린도프릴을포함하는고정된약학적조성물, 및원발성고콜레스테롤혈증또는혼합성고지혈증과함께심근경색및/또는혈관재형성의병력이있는환자에서심혈관질환및 더욱특히관상동맥이벤트의치료및 예방에서상기조성물의용도.

公开(公告)号：KR20180019223A

公开(公告)日：2018-02-23

申请号：KR20187002033

申请日：2016-06-22

Applicant: SERVIER LAB ,  VERNALIS R&D LTD

Inventor： SZLAVIK ZOLTAN ,  KOTSCHY ANDRAS ,  CHANRION MAIEA ,  DEMARLES DIDIER ,  GENESTE OLIVIER ,  DAVIDSON JAMES EDWARD PAUL ,  MURRAY JAMES BROOKE ,  SIPOS SZABOLCS ,  PACZAL ATTILA ,  BALINT BALAZS

IPC: C07D495/04 ,  A61K31/519 ,  A61P35/00 ,  A61P37/00

CPC classification number: C07D495/04

Abstract: 하기화학식 (I)의화합물.상기식에서, R, R, R, R, R, R, R, R, R, R, A 및 n은설명에정의된바와같다. 암치료에사용하기위한이들을함유하는약제.

Abstract translation: 其中R，R，R，R，R，R，R，R，R，R，A和n如说明书中所定义。 含有它们的药物用于治疗癌症。

公开(公告)号：KR20070100657A

公开(公告)日：2007-10-11

申请号：KR20070034003

申请日：2007-04-06

Applicant: SERVIER LAB

Inventor： DELALLEAU BRUNO ,  FIBIANO AGNES ,  MILLAN MARK ,  MOCAER ELISABETH

IPC: A61K31/165 ,  A61P25/22

CPC classification number: A61K31/04 ,  A61K31/165

Abstract: A pharmaceutical composition comprising agomelatine is provided to be used for treating generalized anxiety disorder and provide good acceptability profile to patients without side effects such as withdrawal symptoms occurring when being treated by using a conventional psychotropic drug stops. A pharmaceutical composition for treating generalized anxiety disorder comprises agomelatine or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, or a hydrate thereof, or a pharmaceutically acceptable acid or base addition salt thereof, and at least one pharmaceutically acceptable excipient thereof.

Abstract translation: 提供了含有阿莫西拉的药物组合物，用于治疗广泛性焦虑症，并且对于没有副作用的患者提供良好的可接受性，如通过使用常规精神药物停止治疗时出现的戒断症状。 一种用于治疗广泛性焦虑症的药物组合物包括阿米苏定或N- [2-（7-甲氧基-1-萘基）乙基]乙酰胺或其水合物或其药学上可接受的酸或碱加成盐，以及至少一种药学上可接受的盐 其可接受的赋形剂。

公开(公告)号：JP2003089639A

公开(公告)日：2003-03-28

申请号：JP2002196850

申请日：2002-07-05

Applicant: SERVIER LAB

Inventor： LANGLOIS MICHEL ,  MATHE-ALLAINMAT MONIQUE ,  LEFAS-LE GALL MARIE ,  BENNEJEAN CAROLINE ,  RENARD PIERRE ,  DELAGRANGE PHILIPPE

IPC: C07D339/00 ,  A61K31/16 ,  A61K31/165 ,  A61K31/17 ,  A61K31/335 ,  A61K31/343 ,  A61K31/352 ,  A61K31/353 ,  A61K31/38 ,  A61K31/381 ,  A61K31/395 ,  A61K31/4355 ,  A61K31/437 ,  A61P1/00 ,  A61P3/04 ,  A61P3/10 ,  A61P9/00 ,  A61P15/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/08 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P35/00 ,  A61P43/00 ,  C07C233/18 ,  C07C233/23 ,  C07C233/74 ,  C07C235/34 ,  C07C235/40 ,  C07C275/26 ,  C07D307/79 ,  C07D307/80 ,  C07D307/81 ,  C07D311/92 ,  C07D333/58 ,  C07D333/60 ,  C07D471/04 ,  C07D491/04 ,  C07D491/048 ,  C07D493/04

Abstract: PROBLEM TO BE SOLVED: To obtain a new cyclic compound having pharmacological action on the receptor for a compound having melatonin-like activity. SOLUTION: This new cyclic compound is expressed by formula (I) [R is ORa , SRa , Ra or a cyclic group; A is a cyclic structure group; G1 and G2 are each an alkylene chain or a single bond; B is NR a C(Q)R a , NR a C(Q)NR a R a or C(Q)NR a R a ; and (p) and (q) are numbers satisfying the formula 1

公开(公告)号：JP2002322150A

公开(公告)日：2002-11-08

申请号：JP2002073851

申请日：2002-03-18

Applicant: SERVIER LAB

Inventor： WIERZBICKI MICHEL ,  BOUSSARD MARIE FRANCOISE ,  ROUSSEAU ANNE ,  BOUTIN JEAN-ALBERT ,  DELAGRANGE PHILIPPE

IPC: C07D491/056 ,  A61K31/40 ,  A61K31/403 ,  A61K31/407 ,  A61K31/5377 ,  A61P3/04 ,  A61P3/10 ,  A61P5/00 ,  A61P25/04 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/28 ,  A61P35/00 ,  A61P43/00 ,  C07D209/80 ,  C07D209/94

Abstract: PROBLEM TO BE SOLVED: To provide a compound which exerts a useful pharmacological characteristic toward melatoninergic receptors. SOLUTION: The compound represented by formula (I), not including indeno[1,2-b]indol-10(5H)-one, is provided [wherein, R is H or an arbitrarily substituted alkenyl or an alkyl group; R1 , R2 , R3 , R4 , R5 , R6 , R7 and R8 are each H, an alkyl, an alkenyl, a hydroxy, an alkoxy, an alkenyloxy, an arylalkyl, an arylalkoxy, a carboxy, an acyloxy or an arylcarbonyloxy group, or one of R1 to R8 groups forms an alkylenedioxy group with a group adjacent to the one of R1 to R8 ]. In the compound, when R is not H, at least one of R1 to R8 groups is a hydroxy or an acyloxy group.

公开(公告)号：JP2002226479A

公开(公告)日：2002-08-14

申请号：JP2001384280

申请日：2001-12-18

Applicant: SERVIER LAB

Inventor： DE NANTEUIL GUILLAUME ,  BENOIST ALAIN ,  PASTOUREAU PHILIPPE ,  SABATINI MASSIMO ,  HICKMAN JOHN ,  PIERRE ALAIN ,  TUCKER GORDON

IPC: C07D491/048 ,  A61K31/4433 ,  A61K31/444 ,  A61K31/541 ,  A61P9/10 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D405/14 ,  C07D417/14 ,  C07D491/04

Abstract: PROBLEM TO BE SOLVED: To provide a novel metalloprotease inhibitor that is useful for treating rheumatoid arthritis and the like, a method of producing the same and medicinal composition containing the same. SOLUTION: This invention relates to a novel compound represented by formula (I) [wherein R1 is H or the like; X is O or the like; A represents the compound represented by formula A (wherein Ra is H or the like) or the like], an isomer thereof, an N-oxide thereof and a pharmaceutically acceptable adduct salt.

公开(公告)号：JP2002363157A

公开(公告)日：2002-12-18

申请号：JP2002132484

申请日：2002-05-08

Applicant: SERVIER LAB

Inventor： DE NANTEUIL GUILLAUME ,  PORTEVIN BERNARD ,  BENOIST ALAIN ,  LEVENS NIGEL ,  NOSJEAN OLIVIER ,  HUSSON-ROBERT BERNADETTE ,  BOULANGER MICHELLE

IPC: C07D295/10 ,  A61K31/40 ,  A61K31/426 ,  A61P3/04 ,  A61P3/08 ,  A61P3/10 ,  C07D207/16 ,  C07D277/04 ,  C07D277/06 ,  C07D295/185 ,  C07K5/02

Abstract: PROBLEM TO BE SOLVED: To provide a medicine having dipeptidyl peptidase IV-inhibiting characteristic and useful for treatment of glucose intolerance, hyperglycemia and related disorders. SOLUTION: This invention relates to a compound represented by formula (I) [wherein the ring A is a 5-membered nitrogen-containing heterocycle which may be substituted with cyano group; Ak is a straight-chain or branched (1-6C) alkylene chain; X is a single bond or the like; R1 and R2 are each hydrogen atom or the like; R3 is a straight-chain or branched chain (1-6C) alkyl or the like; Y represents CH-NO2 or the like], existing tautomer thereof, optical isomer thereof and addition salt of pharmaceutically acceptable acid thereof, a method for synthesizing the compound and, a pharmaceutical composition containing the compound.

公开(公告)号：JP2002265448A

公开(公告)日：2002-09-18

申请号：JP2002009645

申请日：2002-01-18

Applicant: SERVIER LAB

Inventor： CASARA PATRICK ,  LE DIGUARHER THIERRY ,  DOREY GILBERT ,  HICKMAN JOHN ,  PIERRE ALAIN ,  TUCKER GORDON ,  GUILBAUD NICOLAS

IPC: C07C317/00 ,  A61K31/4164 ,  A61K31/417 ,  A61K31/4178 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/454 ,  A61P9/00 ,  A61P9/10 ,  A61P25/00 ,  A61P35/00 ,  C07D213/36 ,  C07D213/38 ,  C07D213/57 ,  C07D233/54 ,  C07D233/58 ,  C07D233/61 ,  C07D233/64 ,  C07D401/06

Abstract: PROBLEM TO BE SOLVED: To provide a compound having a specific structure, selectively inhibiting FTase with respect to GGTase and useful for the treatment of diseases relating to the intracellular signal transduction through Ras protein, etc., and the investigation of pathology relating to angiogenetic amplification. SOLUTION: The objective compound is expressed by formula (I) [X is a bond, an alkylene, S(O)n or the like; Y is an aryl, a heteroaryl or the like; R1 to R4 are each independently H, an aryl or the like or together form a bond, a condensed benzene ring or the like; T is CH(R5 ) (R5 is H or the like) or the like; V is H, a substituted aryl or the like; A2 is [C(R6 ) (R'6 )] (R6 and R'6 are each H or the like; and (p) is 0-4); and R7 and R8 are each H or the like]. The invention further relates to its isomer, diastereomer, pharmacologically permissible acid or base and its addition salt.